Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Amgen buys Ilypsa for $420mm in cash

Executive Summary

Amgen has acquired Ilypsa (non-absorbed therapeutics for renal disorders) for $420mm in cash. Ilypsa will now become a wholly owned subsidiary of Amgen.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Payment Includes Cash
    • Acquisition of Private Biotech
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register